Karyopharm Therapeutics: CHMP Recommended Approval of the Firm’s Product NEXPOVIO® for Multiple Melanoma in Europe.

Karyopharm Therapeutics 
Karyopharm Therapeutics (KPTI) and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of NEXPOVIO® (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor, in combination with once weekly . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.